“Results of Two Sequential Phase II Studies of Interleukin-2 (IL2) in Metastatic Renal Cell Carcinoma and Melanoma: High-Dose Continuous Intravenous IL2 Infusion and Subcutaneous IL2 Administration in Combination With Alpha Interferon”. Revista De Medicina De La Universidad De Navarra, vol. 40, no. 3, Apr. 2017, pp. 6-12, https://doi.org/10.15581/021.8892.